High-throughput insertional mutagenesis screens in mice to identify oncogenic networks

Nature Reviews Cancer

Volumn 9, Issue 6, 2009, Pages 389-399

  Kool, Jaap ^a   Berns, Anton ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

CANCER RESISTANCE; CARCINOGENESIS; CLONING; GENE INSERTION; GENE INTERACTION; GENE SEQUENCE; HUMAN; MEDICAL RESEARCH; MUTAGENESIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SCREENING; TRANSPOSON; TUMOR GENE; TUMOR SUPPRESSOR GENE; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; MOUSE; NEOPLASM; PROCEDURES;

ANIMALS; MICE; MUTAGENESIS, INSERTIONAL; NEOPLASMS;

EID: 67649450275     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2647     Document Type: Review

References (78)

1. Uren,A. G., Kool, J., Berns, A. &van Lohuizen, M. Retroviral insertional mutagenesis: past, present and future. Oncogene 24, 7656-7672 (2005).
2. Jonkers, J. & Berns, A. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim. Biophys.Acta 1287, 29-57 (1996).
3. ARF-and p53-deficient mice identifies cancer genes and their collaborative networks. Cell 133, 727-741 (2008).
4. Jonkers, J., Korswagen, H. C., Acton, D., Breuer, M. & Berns, A. Activation of a novel proto-oncogene, Frat 1, contributes to progression of mouse T-cell lymphomas. EMBO J. 16, 441-450 (1997).
5. Nihrane, A., Fujita, K., Willey, R., Lyu, M. S. & Silver, J. Murine leukemia virus envelope protein in transgenicmouse serum blocks infection in vitro. J. Virol. 70, 1882-1889 (1996).
6. Ikeda, H. & Sugimura, H. Fv-4 resistance gene: a truncated endogenous murine leukemia virus with ecotropic interference properties. J. Virol. 63, 5405-5412 (1989).
7. Ott, D. & Rein, A. Basis for receptor specificity of nonecotropic murine leukemia virus surface glycoprotein gp70SU. J. Virol. 66, 4632-4638 (1992).
8. Heidmann,T., Heidmann,O. & Nicolas, J. F. An indicator gene to demonstrate intracellular transposition of defective retroviruses. Proc. Natl Acad. Sci. USA 85, 2219-2223 (1988).
9. Tchenio, T. & Heidmann, T. Defective retroviruses can disperse in the human genome by intracellular transposition. J. Virol. 65, 2113-2118 (1991).
10. Dzuris, J. L., Zhu, W., Kapkov, D., Golovkina, T. V. & Ross, S. R. Expression of mouse mammary tumour virus envelope protein does not prevent superinfection in vivo or in vitro. Virology 263, 418-426 (1999).
11. Suzuki, T., Minehata, K., Akagi, K., Jenkins, N. A. & Copeland, N. G. Tumour suppressor gene identification using retroviral insertional mutagenesis in Blm-deficient mice. EMBOJ. 25, 3422-3431 (2006).
12. Suzuki, T. et al. New genes involved in cancer identified by retroviral tagging. Nature Genet. 32, 166-174 (2002).
13. Stewart, M. et al. Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas. Cancer Res. 67, 5126-5133 (2007).
14. Mikkers, H. et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nature Genet. 32, 153-159 (2002).
15. Erkeland, S. J. et al. Large-scale identification of disease genes involved in acute myeloid leukemia. J. Virol. 78, 1971-1980 (2004).
16. Lund, A. H. et al. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nature Genet. 32, 160-165 (2002).
17. Theodorou, V. et al. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nature Genet. 39, 759-769 (2007).
18. Kim, R. et al. Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas. J. Virol. 77, 2056-2062 (2003).
19. Hasemann, M. S. et al. Mutation of C/EBPα predisposes to the development of myeloid leukemia in a retroviral insertional mutagenesis screen. Blood 111, 4309-4321 (2008).
20. Shendure, J. & Ji, H. Next-generation DNA sequencing. Nature Biotechnol. 26, 1135-1145 (2008).
21. Dupuy, A. J., Akagi, K., Largaespada, D. A., Copeland, N. G. & Jenkins, N. A. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436, 221-226 (2005).
22. Collier, L. S., Carlson, C. M., Ravimohan, S., Dupuy, A. J. & Largaespada, D. A. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436, 272-276 (2005).
23. Carlson, C. M. & Largaespada, D. A. Insertional mutagenesis in mice: new perspectives and tools. Nature Rev. Genet. 6, 568-580 (2005).
24. Keng, V. W. et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nature Biotechnol. 27, 264-274 (2009).
25. Starr, T. K. et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323, 1747-1750 (2009).
26. Beverly, L. J., Felsher, D. W. & Capobianco, A. J. Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Res. 65, 7159-7168 (2005).
27. IC- induced T cell leukemogenesis. Cancer Cell 3, 551-564 (2003).
28. Iwasaki, M. et al. Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model. Blood 105, 784-793 (2005).
29. Castilla, L. H. et al. Identification of genes that synergize with Cbfb-MYH 11 in the pathogenesis of acute myeloid leukemia. Proc. NatlAcad. Sci. USA 101, 4924-4929 (2004).
30. Feldman, B. J., Reid, T. R. &Cleary, M. L. Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice. Oncogene 15, 2735-2742 (1997).
31. Slape, C. et al. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res. 67, 5148-5155 (2007).
32. Li, J. et al. Leukaemia disease genes: large-scale cloning and pathway predictions. Nature Genet. 23, 348-353 (1999).
33. Erkeland, S. J. et al. Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia. Cancer Res. 66, 622-626 (2006).
34. Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533-538 (1985).
35. Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumours. Cancer Cell 4, 223-238 (2003).
36. Jacobs, J. J. et al. Bmi-1 collaborates with c-Myc in tumourigenesis by inhibiting c-Myc- induced apoptosis via INK4a/ARF. Genes Dev. 13, 2678-2690 (1999).
37. van der Lugt, N. M. et al. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBOJ. 14, 2536-2544 (1995).
38. Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 679-683 (2008).
39. Lazo, P. A., Lee, J. S. &Tsichlis, P. N. Long-distance activation of the Myc protooncogene by provirus insertion in Mlvi-1 or Mlvi-4 in ratT-cell lymphomas. Proc. NatlAcad. Sci. USA 87, 170-173 (1990).
40. Hickson, I. D. RecQ helicases: caretakers of the genome. Nature Rev. Cancer 3, 169-178 (2003).
41. Luo, G. et al. Cancer predisposition caused by elevated mitotic recombination in Bloom mice. Nature Genet. 26, 424-429 (2000).
42. Garrett-Engele, C. M. et al. A mechanism misregulating p27 in tumours discovered in a functional genomic screen. PLoS Genet. 3, e219 (2007).
43. Tsihlias, J., Kapusta, L. & Slingerland, J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50, 401-423 (1999).
44. Park, M. S. et al. p27 and Rb are on overlapping pathways suppressing tumourigenesis in mice. Proc. NatlAcad. Sci. USA 96, 6382-6387 (1999).
45. Pinkel, D. & Albertson, D. G. Array comparative genomic hybridization and its applications in cancer. Nature Genet. 37, S11 -S17 (2005).
46. Carrasco, D. R. et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9, 313-325 (2006).
47. Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007).
48. Sjoblom,T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
49. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
50. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801 -1806 (2008).
51. Fujino, Y., Ohno, K. &Tsujimoto, H. Molecular pathogenesis of feline leukemia virus-induced malignancies: insertional mutagenesis. Vet. Immunol. Immunopathol. 123, 138-143 (2008).
52. Kanter, M. R., Smith, R. E. & Hayward, W. S. Rapid induction of B-cell lymphomas: insertional activation of c-myb by avian leukosis virus. J. Virol. 62, 1423-1432 (1988).
53. van Agthoven, T. et al. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res. Treat. 114, 23-30 (2009).
54. Dorssers, L. C., van, A. T., Dekker, A., van Agthoven, T. L. & Kok, E. M. Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. Mol. Endocrinol. 7, 870-878 (1993).
55. van der, F. S. et al. Bcar1/p1 30Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J. Natl Cancer Inst. 92, 120-127 (2000).
56. Miething, C. et al. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc. NatlAcad. Sci. USA 104, 4594-4599 (2007).
57. Johansson, F. K., Goransson, H. & Westermark, B. Expression analysis of genes involved in brain tumour progression driven by retroviral insertional mutagenesis in mice. Oncogene 24, 3896-3905 (2005).
58. Hanai, S. et al. Integration of human T-cell leukemia virus type 1 in genes of leukemia cells of patients with adult T-cell leukemia. Cancer Sci. 95, 306-310 (2004).
59. Killebrew, D. & Shiramizu, B. Pathogenesis of HIV-associated non-Hodgkin lymphoma. Curr. HIV Res. 2, 215-221 (2004).
60. Thrasher, A. J. et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature 443, E5-E6; discussion E6-E7 (2006).
61. de Ridder, J., Uren, A., Kool, J., Reinders, M. & Wessels, L. Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput. Biol. 2, e1 66 (2006).
62. Wu, X., Li, Y., Crise, B. & Burgess, S. M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751 (2003).
63. Berry, C., Hannenhalli, S., Leipzig, J. & Bushman, F. D. Selection of target sites for mobile DNA integration in the human genome. PLoS Comput. Biol. 2, e1 57 (2006).
64. Lewinski, M. K. et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2, e60 (2006).
65. Mitchell, R. S. et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, e234 (2004).
66. Felice, B. et al. Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS ONE 4, e4571 (2009).
67. Sauvageau, M. et al. Quantitative expression profiling guided by common retroviral insertion sites reveals novel and cell type specific cancer genes in leukemia. Blood 111, 790-799 (2008).
68. Su, Q. et al. A DNA transposon-based approach to validate oncogenic mutations in the mouse. Proc. Natl Acad. Sci. USA 105, 19904-19909 (2008).
69. Wilson, M. H., Coates, C. J. & George, A. L. Jr. PiggyBac transposon-mediated gene transfer in human cells. Mol. Ther. 15, 139-145 (2007).
70. Carlson, C.M.et al. Transposon mutagenesis of the mouse germline. Genetics 165, 243-256 (2003).
71. van Lohuizen, M., Breuer, M. & Berns, A. N-myc is frequently activated by proviral insertion in MuLV-inducedTcell lymphomas. EMBOJ. 8, 133-136 (1989).
72. Girard, L. &Jolicoeur, P. A full-length Notch1 allele is dispensable for transformation associated with a provirally activated truncated Notch 1 allele in Moloney MuLV-infected MMTVD/myc transgenic mice. Oncogene 16, 517-522 (1998).
73. Weng, A. P. et al. Activating mutations of NOTCH 1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004).
74. Yang, L. T. et al. Fringe glycosyltransferases differentially modulate Notch 1 proteolysis induced by Delta 1 and Jagged 1. Mol. Biol. Cell 16, 927-942 (2005).
75. Haines, N. & Irvine, K. D. Glycosylation regulates Notch signalling. Nature Rev. Mol. Cell Biol. 4, 786-797 (2003).
76. Moloney, D. J. et al. Fringe is a glycosyltransferase that modifies Notch. Nature 406, 369-375 (2000).
77. Largaespada, D. A.,Shaughnessy, J. D. Jr, Jenkins, N. A. & Copeland, N. G. Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. J. Virol. 69, 5095-5102 (1995).
78. Cho, B. C. et al. Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas. J. Virol. 69, 7138-7146 (1995).